Treating CML in Developing Countries
The whole world of CML changed in the early 2000s with the introduction of imatinib and TKIs, however, the situation in developing countries can be significantly different from Europe and USA, as discussed by Prof Hemant Malhotra in this podcast.
Short-backs may encompass the molecular diagnosis and monitoring of the disease (not everywhere available) as well as the cost of drugs and medical expense coverage. On the other hand, the relative affordability of generic TKIs may cause skipping of expensive diagnostic procedures before starting treatment, whereas their current prolonged life…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.